https://stock.noler.com/us/stock/zosano-pharma-corp https://stock.noler.com/us/stock/zosano-pharma-corp/accounts-payable https://stock.noler.com/us/stock/zosano-pharma-corp/accounts-receivable https://stock.noler.com/us/stock/zosano-pharma-corp/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/zosano-pharma-corp/accretion-expense https://stock.noler.com/us/stock/zosano-pharma-corp/accretion-of-discount https://stock.noler.com/us/stock/zosano-pharma-corp/accrued-employee-benefits-current https://stock.noler.com/us/stock/zosano-pharma-corp/accrued-professional-fees-current-and-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/accumulated-capitalized-interest-costs https://stock.noler.com/us/stock/zosano-pharma-corp/accumulated-depreciation https://stock.noler.com/us/stock/zosano-pharma-corp/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/zosano-pharma-corp/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/zosano-pharma-corp/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/zosano-pharma-corp/amortization-of-financing-costs-and-discounts https://stock.noler.com/us/stock/zosano-pharma-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/zosano-pharma-corp/aoci https://stock.noler.com/us/stock/zosano-pharma-corp/asset-impairment-charges https://stock.noler.com/us/stock/zosano-pharma-corp/asset-retirement-obligation-accretion-expense https://stock.noler.com/us/stock/zosano-pharma-corp/asset-retirement-obligation-current https://stock.noler.com/us/stock/zosano-pharma-corp/assets-fair-value-disclosure https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-amortized-cost https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-debt-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-debt-maturities-next-rolling-twelve-months-fair-value https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-debt-maturities-single-maturity-date https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-debt-securities https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-gross-realized-gain-loss-net https://stock.noler.com/us/stock/zosano-pharma-corp/available-for-sale-securities https://stock.noler.com/us/stock/zosano-pharma-corp/basic-shares https://stock.noler.com/us/stock/zosano-pharma-corp/capital-expenditures https://stock.noler.com/us/stock/zosano-pharma-corp/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/zosano-pharma-corp/capital-lease-obligations https://stock.noler.com/us/stock/zosano-pharma-corp/capital-lease-obligations-current https://stock.noler.com/us/stock/zosano-pharma-corp/capital-lease-obligations-incurred https://stock.noler.com/us/stock/zosano-pharma-corp/capital-lease-obligations-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/capital-leases-future-minimum-payments-due-current https://stock.noler.com/us/stock/zosano-pharma-corp/capital-leases-future-minimum-payments-due-in-four-years https://stock.noler.com/us/stock/zosano-pharma-corp/capital-leases-future-minimum-payments-due-in-three-years https://stock.noler.com/us/stock/zosano-pharma-corp/capital-leases-future-minimum-payments-due-in-two-years https://stock.noler.com/us/stock/zosano-pharma-corp/capital-leases-future-minimum-payments-interest-included-in-payments https://stock.noler.com/us/stock/zosano-pharma-corp/capital-leases-future-minimum-payments-net-minimum-payments https://stock.noler.com/us/stock/zosano-pharma-corp/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/zosano-pharma-corp/cash-and-equivalents https://stock.noler.com/us/stock/zosano-pharma-corp/cash-and-restricted-cash https://stock.noler.com/us/stock/zosano-pharma-corp/cash-and-restricted-cash-change-excluding-exchange-rate-effect https://stock.noler.com/us/stock/zosano-pharma-corp/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/zosano-pharma-corp/cash-flow-breakdown https://stock.noler.com/us/stock/zosano-pharma-corp/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/zosano-pharma-corp/class-of-warrant-or-right-number-of-securities-called-by-each-warrant-or-right https://stock.noler.com/us/stock/zosano-pharma-corp/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/zosano-pharma-corp/class-of-warrant-or-right-outstanding https://stock.noler.com/us/stock/zosano-pharma-corp/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/zosano-pharma-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/zosano-pharma-corp/common-stock-value https://stock.noler.com/us/stock/zosano-pharma-corp/comprehensive-income https://stock.noler.com/us/stock/zosano-pharma-corp/concentration-risk-credit-risk-financial-instrument-maximum-exposure https://stock.noler.com/us/stock/zosano-pharma-corp/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/zosano-pharma-corp/contract-liability https://stock.noler.com/us/stock/zosano-pharma-corp/contracts-revenue https://stock.noler.com/us/stock/zosano-pharma-corp/convertible-long-term-notes-payable https://stock.noler.com/us/stock/zosano-pharma-corp/convertible-notes-payable-current https://stock.noler.com/us/stock/zosano-pharma-corp/cost-of-revenue https://stock.noler.com/us/stock/zosano-pharma-corp/costs-and-expenses https://stock.noler.com/us/stock/zosano-pharma-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/zosano-pharma-corp/current-assets https://stock.noler.com/us/stock/zosano-pharma-corp/current-liabilities https://stock.noler.com/us/stock/zosano-pharma-corp/current-portion-of-long-term-debt https://stock.noler.com/us/stock/zosano-pharma-corp/debt-carrying-amount https://stock.noler.com/us/stock/zosano-pharma-corp/debt-conversion-original-debt-amount https://stock.noler.com/us/stock/zosano-pharma-corp/debt-decrease-forgiveness https://stock.noler.com/us/stock/zosano-pharma-corp/debt-issuance-costs-incurred-during-noncash-or-partial-noncash-transaction https://stock.noler.com/us/stock/zosano-pharma-corp/debt-issuance-costs-line-of-credit-arrangements-net https://stock.noler.com/us/stock/zosano-pharma-corp/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/zosano-pharma-corp/debt-maturing-in-year-four https://stock.noler.com/us/stock/zosano-pharma-corp/debt-maturing-in-year-three https://stock.noler.com/us/stock/zosano-pharma-corp/debt-maturing-in-year-two https://stock.noler.com/us/stock/zosano-pharma-corp/debt-maturing-remainder-of-fiscal-year https://stock.noler.com/us/stock/zosano-pharma-corp/debt-unamortized-discount https://stock.noler.com/us/stock/zosano-pharma-corp/debt-unamortized-premium https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-offering-costs https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-rent-credit https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-revenue https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-capital-loss-carryforwards https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-gross https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-inventory https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-other https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-deferred-rent https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-liabilities-leasing-arrangements https://stock.noler.com/us/stock/zosano-pharma-corp/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/zosano-pharma-corp/depreciation https://stock.noler.com/us/stock/zosano-pharma-corp/depreciation-and-amortization https://stock.noler.com/us/stock/zosano-pharma-corp/diluted-shares https://stock.noler.com/us/stock/zosano-pharma-corp/dividends-per-share https://stock.noler.com/us/stock/zosano-pharma-corp/due-from-joint-ventures-current https://stock.noler.com/us/stock/zosano-pharma-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/zosano-pharma-corp/effective-tax-rate https://stock.noler.com/us/stock/zosano-pharma-corp/eps https://stock.noler.com/us/stock/zosano-pharma-corp/eps-basic https://stock.noler.com/us/stock/zosano-pharma-corp/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-interest-expense https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-interest-payment-on-liability https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-current https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due-after-year-five https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due-next-twelve-months https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due-year-five https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due-year-four https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due-year-three https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-due-year-two https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-principal-payments https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-right-of-use-asset-accumulated-amortization https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-right-of-use-asset-amortization https://stock.noler.com/us/stock/zosano-pharma-corp/finance-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/zosano-pharma-corp/financing-cash-flow https://stock.noler.com/us/stock/zosano-pharma-corp/form-d-other https://stock.noler.com/us/stock/zosano-pharma-corp/form-d-stocks https://stock.noler.com/us/stock/zosano-pharma-corp/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/zosano-pharma-corp/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/zosano-pharma-corp/general-and-administrative-expense https://stock.noler.com/us/stock/zosano-pharma-corp/ground-leases-accumulated-amortization https://stock.noler.com/us/stock/zosano-pharma-corp/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/zosano-pharma-corp/income-tax https://stock.noler.com/us/stock/zosano-pharma-corp/income-taxes-paid https://stock.noler.com/us/stock/zosano-pharma-corp/income-taxes-paid-2 https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-accrued-interest-receivable-net https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-accrued-liabilities-and-other-operating-liabilities https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-due-from-related-parties-current https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-interest-payable-net https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/zosano-pharma-corp/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/zosano-pharma-corp/insider-transactions-corporate-securities https://stock.noler.com/us/stock/zosano-pharma-corp/insider-transactions-stock-options https://stock.noler.com/us/stock/zosano-pharma-corp/insider-transactions-stock-units https://stock.noler.com/us/stock/zosano-pharma-corp/insider-transactions-warrants https://stock.noler.com/us/stock/zosano-pharma-corp/insider-transactions-warrants/purchases https://stock.noler.com/us/stock/zosano-pharma-corp/interest-and-debt-expense https://stock.noler.com/us/stock/zosano-pharma-corp/interest-expense https://stock.noler.com/us/stock/zosano-pharma-corp/interest-expense-on-debt https://stock.noler.com/us/stock/zosano-pharma-corp/interest-income-expense-nonoperating-net https://stock.noler.com/us/stock/zosano-pharma-corp/interest-paid https://stock.noler.com/us/stock/zosano-pharma-corp/interest-paid-net https://stock.noler.com/us/stock/zosano-pharma-corp/interest-receivable-current https://stock.noler.com/us/stock/zosano-pharma-corp/investing-cash-flow https://stock.noler.com/us/stock/zosano-pharma-corp/investment-income-interest https://stock.noler.com/us/stock/zosano-pharma-corp/lease-cost https://stock.noler.com/us/stock/zosano-pharma-corp/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/zosano-pharma-corp/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/zosano-pharma-corp/license-costs https://stock.noler.com/us/stock/zosano-pharma-corp/licenses-revenue https://stock.noler.com/us/stock/zosano-pharma-corp/line-of-credit-facility-remaining-borrowing-capacity https://stock.noler.com/us/stock/zosano-pharma-corp/long-term-debt https://stock.noler.com/us/stock/zosano-pharma-corp/long-term-purchase-commitment-amount https://stock.noler.com/us/stock/zosano-pharma-corp/marketable-securities-current https://stock.noler.com/us/stock/zosano-pharma-corp/marketable-securities-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/net-cash-from-financing-activities https://stock.noler.com/us/stock/zosano-pharma-corp/net-cash-from-investing-activities https://stock.noler.com/us/stock/zosano-pharma-corp/net-cash-from-operating-activities https://stock.noler.com/us/stock/zosano-pharma-corp/net-change-in-cash https://stock.noler.com/us/stock/zosano-pharma-corp/net-income https://stock.noler.com/us/stock/zosano-pharma-corp/number-of-operating-segments https://stock.noler.com/us/stock/zosano-pharma-corp/number-of-plaintiffs https://stock.noler.com/us/stock/zosano-pharma-corp/number-of-reportable-segments https://stock.noler.com/us/stock/zosano-pharma-corp/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/zosano-pharma-corp/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/zosano-pharma-corp/operating-cash-flow https://stock.noler.com/us/stock/zosano-pharma-corp/operating-expenses https://stock.noler.com/us/stock/zosano-pharma-corp/operating-income https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-assets https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-cost https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-liability https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-liability-current https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-2 https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-current https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/zosano-pharma-corp/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/zosano-pharma-corp/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/zosano-pharma-corp/operating-leases-rent-expense-net https://stock.noler.com/us/stock/zosano-pharma-corp/other-accrued-liabilities-current https://stock.noler.com/us/stock/zosano-pharma-corp/other-accrued-liabilities-current-and-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/other-current-assets https://stock.noler.com/us/stock/zosano-pharma-corp/other-noncash-income-expense https://stock.noler.com/us/stock/zosano-pharma-corp/other-noncurrent-assets https://stock.noler.com/us/stock/zosano-pharma-corp/other-noncurrent-liabilities https://stock.noler.com/us/stock/zosano-pharma-corp/other-nonoperating-income https://stock.noler.com/us/stock/zosano-pharma-corp/other-nonoperating-income-expense https://stock.noler.com/us/stock/zosano-pharma-corp/other-operating-activities-cash-flow-statement https://stock.noler.com/us/stock/zosano-pharma-corp/other-receivables-net-current https://stock.noler.com/us/stock/zosano-pharma-corp/other-sundry-liabilities-current https://stock.noler.com/us/stock/zosano-pharma-corp/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/zosano-pharma-corp/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/zosano-pharma-corp/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/zosano-pharma-corp/payments-for-postemployment-benefits https://stock.noler.com/us/stock/zosano-pharma-corp/payments-for-proceeds-from-investments https://stock.noler.com/us/stock/zosano-pharma-corp/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/zosano-pharma-corp/payments-for-restructuring https://stock.noler.com/us/stock/zosano-pharma-corp/payments-of-debt-extinguishment-costs https://stock.noler.com/us/stock/zosano-pharma-corp/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/zosano-pharma-corp/payments-to-acquire-investments https://stock.noler.com/us/stock/zosano-pharma-corp/payments-to-acquire-marketable-securities https://stock.noler.com/us/stock/zosano-pharma-corp/postemployment-benefits-period-expense https://stock.noler.com/us/stock/zosano-pharma-corp/preferred-shares-facts https://stock.noler.com/us/stock/zosano-pharma-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/zosano-pharma-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/zosano-pharma-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/zosano-pharma-corp/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/zosano-pharma-corp/preferred-stock-value https://stock.noler.com/us/stock/zosano-pharma-corp/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/zosano-pharma-corp/prepaid-insurance https://stock.noler.com/us/stock/zosano-pharma-corp/prepaid-rent https://stock.noler.com/us/stock/zosano-pharma-corp/pretax-income https://stock.noler.com/us/stock/zosano-pharma-corp/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-debt-net-of-issuance-costs https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-issuance-of-debt https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-issuance-of-unsecured-debt https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-issuance-of-warrants https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-long-term-capital-lease-obligations https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-related-party-debt https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-sale-and-maturity-of-marketable-securities https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-sale-of-longterm-investments https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-sale-of-other-assets https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/zosano-pharma-corp/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/zosano-pharma-corp/profit-loss https://stock.noler.com/us/stock/zosano-pharma-corp/property-plant-and-equipment-and-finance-lease-right-of-use-asset-after-accumulated-depreciation-and-amortization https://stock.noler.com/us/stock/zosano-pharma-corp/property-plant-and-equipment-and-finance-lease-right-of-use-asset-before-accumulated-depreciation-and-amortization https://stock.noler.com/us/stock/zosano-pharma-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/zosano-pharma-corp/property-plant-equipment https://stock.noler.com/us/stock/zosano-pharma-corp/public-float https://stock.noler.com/us/stock/zosano-pharma-corp/receivables-net-current https://stock.noler.com/us/stock/zosano-pharma-corp/repayments-of-debt https://stock.noler.com/us/stock/zosano-pharma-corp/repayments-of-lines-of-credit https://stock.noler.com/us/stock/zosano-pharma-corp/research-and-development https://stock.noler.com/us/stock/zosano-pharma-corp/restricted-cash https://stock.noler.com/us/stock/zosano-pharma-corp/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/zosano-pharma-corp/restricted-cash-and-cash-equivalents-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/restricted-cash-current https://stock.noler.com/us/stock/zosano-pharma-corp/restricted-cash-noncurrent https://stock.noler.com/us/stock/zosano-pharma-corp/restructuring-and-related-cost-number-of-positions-eliminated https://stock.noler.com/us/stock/zosano-pharma-corp/restructuring-and-related-cost-number-of-positions-eliminated-period-percent https://stock.noler.com/us/stock/zosano-pharma-corp/restructuring-charges https://stock.noler.com/us/stock/zosano-pharma-corp/retained-earnings https://stock.noler.com/us/stock/zosano-pharma-corp/revenue https://stock.noler.com/us/stock/zosano-pharma-corp/revenue-from-contract-with-customer-excluding-assessed-tax https://stock.noler.com/us/stock/zosano-pharma-corp/right-of-use-asset-obtained-in-exchange-for-finance-lease-liability https://stock.noler.com/us/stock/zosano-pharma-corp/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/zosano-pharma-corp/sale-of-stock-consideration-received-on-transaction https://stock.noler.com/us/stock/zosano-pharma-corp/sales-revenue-net https://stock.noler.com/us/stock/zosano-pharma-corp/secured-debt-current https://stock.noler.com/us/stock/zosano-pharma-corp/secured-long-term-debt https://stock.noler.com/us/stock/zosano-pharma-corp/settlement-of-asset-retirement-obligations-through-noncash-payments-amount https://stock.noler.com/us/stock/zosano-pharma-corp/severance-costs https://stock.noler.com/us/stock/zosano-pharma-corp/share-based-compensation-shares-authorized-under-stock-option-plans-exercise-price-range-number-of-exercisable-options https://stock.noler.com/us/stock/zosano-pharma-corp/shareholders-equity https://stock.noler.com/us/stock/zosano-pharma-corp/shares-authorized https://stock.noler.com/us/stock/zosano-pharma-corp/shares-issued https://stock.noler.com/us/stock/zosano-pharma-corp/shares-issued-price-per-share https://stock.noler.com/us/stock/zosano-pharma-corp/shares-issued-shares-new-issues https://stock.noler.com/us/stock/zosano-pharma-corp/short-term-debt https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-award-vesting-rights-percentage https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-number-of-additional-shares-authorized https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-options-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-rsu-forfeited-in-period https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-rsu-grants-in-period https://stock.noler.com/us/stock/zosano-pharma-corp/stock-award-rsu-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/zosano-pharma-corp/stock-based-compensation https://stock.noler.com/us/stock/zosano-pharma-corp/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/zosano-pharma-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/zosano-pharma-corp/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/zosano-pharma-corp/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/zosano-pharma-corp/stock-issued-shares-issued-value-restricted-stock-award-gross https://stock.noler.com/us/stock/zosano-pharma-corp/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-exercisable-number https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-grants-in-period https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/zosano-pharma-corp/stock-options-vested-number-of-shares https://stock.noler.com/us/stock/zosano-pharma-corp/stock-split-ratio https://stock.noler.com/us/stock/zosano-pharma-corp/stockholders-equity-note-changes-in-capital-structure-subsequent-changes-to-number-of-common-shares https://stock.noler.com/us/stock/zosano-pharma-corp/straight-line-rent https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/zosano-pharma-corp/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/zosano-pharma-corp/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/zosano-pharma-corp/total-assets https://stock.noler.com/us/stock/zosano-pharma-corp/total-liabilities https://stock.noler.com/us/stock/zosano-pharma-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/zosano-pharma-corp/total-long-term-debt https://stock.noler.com/us/stock/zosano-pharma-corp/unbilled-receivables-current https://stock.noler.com/us/stock/zosano-pharma-corp/unrealized-gain-loss-on-marketable-securities-cost-method-investments-and-other-investments https://stock.noler.com/us/stock/zosano-pharma-corp/unrecognized-tax-benefits https://stock.noler.com/us/stock/zosano-pharma-corp/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/zosano-pharma-corp/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/zosano-pharma-corp/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/zosano-pharma-corp/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/zosano-pharma-corp/weighted-average-number-of-share-outstanding-basic-and-diluted